<![CDATA[Background: Protease inhibitor (PI) resistance surveillance requires denominators specific to treatment-experienced patients with successful protease (PR) sequencing. Indonesian reports differ in their populations, treatment histories and sequencing success.Objective: To estimate the prevalence of at least one major PI mutation among antiretroviral therapy (ART)-experienced Indonesian patients with successfully sequenced PR genes, and to reconcile two supplied systematic-review manuscripts into a single working evidence set.Methods: A binomial-normal random-effects model with a logit link and a profile-likelihood interval was used; crude proportions carry exact binomial intervals. JBI prevalence-study domains were reassessed. Geographic, publication-period and sensitivity analyses were treated as exploratory.Results: Six cohorts contributed 186 PR-sequenced ART-experienced patients and one patient positive for a major PI mutation. The pooled prevalence was 0.54% (95% profile-likelihood CI <0.01-2.38%), with fitted between-study variance at zero. The crude proportion was 0.54% (exact 95% CI 0.01-2.96%). Geographic and publication-period comparisons did not establish differences. A Makassar report with an unresolved ART-specific PR denominator was retained for narrative and conditional sensitivity analyses; adding its two positive patients yielded pooled point estimates of 1.04-1.06%.Conclusion: Low observed frequency does not establish PI regimen durability or the origin of resistance. Original search histories, screening logs and parts of the extraction and appraisal were unavailable, so completeness and the historical review methods remain unverified. The findings describe a provisional working evidence set that requires a documented search and a source-data audit.]]>
